The Greater Cannabis Company, Inc. reported no revenue for the fiscal year ending December 31, 2025, consistent with the previous year. The company’s operating expenses increased to $183,005 from $156,276 in 2024, contributing to a net loss of $331,612, compared to a net loss of $179,041 in the prior year. The increase in losses is attributed to higher operational costs and a loss on the conversion of notes payable amounting to $227,756. The company ended the year with only $815 in cash, a significant decrease from $57,368 in 2024, raising concerns about its liquidity and ability to continue operations.
In terms of strategic developments, the company has shifted its focus towards the development and commercialization of cannabinoid therapeutics. This includes a licensing agreement with Shaare Zedek Scientific Ltd. for a novel cannabinoid therapy aimed at treating various neuropsychiatric disorders. The company is currently awaiting the sourcing of specialized active pharmaceutical ingredients necessary for a Phase II Clinical Trial, which is expected to take 18 to 24 months to complete once initiated. The company has also implemented a reverse stock split of 1-for-1,500, effective October 16, 2025, and created a new class of Series B Convertible Preferred Stock.
Operationally, the company has made no significant progress in customer acquisition or product sales, as indicated by the absence of revenue. The total liabilities decreased to $742,464 from $898,058 in 2024, primarily due to the reduction in notes payable. However, the company continues to face challenges in attracting and retaining qualified personnel, which is critical for its planned development and growth. The employee headcount remains low, with only one full-time employee, the CEO.
Looking ahead, the company acknowledges several risks that could impact its future performance, including regulatory changes in the cannabis industry and the need for additional financing to support its clinical trials and operational costs. The management's plans to secure funding remain uncertain, and the company has expressed that it may not be able to continue as a going concern without raising additional capital. The outlook remains cautious as the company navigates these challenges while attempting to advance its therapeutic product development.
About Greater Cannabis Company, Inc.
The Greater Cannabis Company develops and commercializes cannabinoid therapeutics, focusing on innovative drug delivery platforms and neuropsychiatric treatments. It holds licenses for cannabinoid-based therapies targeting conditions like autism and Parkinson’s disease. The company operates in the medical cannabis sector, emphasizing research, clinical development, and strategic partnerships, with a business model centered on developing proprietary therapeutics and licensing technologies in a highly regulated industry.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.